Targeting of Miz-1 is essential for Myc-mediated apoptosis

Jagruti H Patel1, Steven B McMahon

  • 1The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

Insights

The oncoprotein c-Myc

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • The c-Myc oncoprotein is a key regulator in human cancers.
  • c-Myc influences gene transcription, activating or repressing target genes.
  • Miz-1 inactivation by c-Myc is implicated in its oncogenic functions.

Purpose of the Study:

  • To investigate the necessity of Miz-1 inactivation for c-Myc's roles in cell cycle progression, transformation, and apoptosis.
  • To elucidate the biochemical mechanisms underlying c-Myc's opposing biological functions.

Main Methods:

  • Utilized short hairpin RNA (shRNA) for c-Myc knockdown.
  • Employed a c-Myc mutant defective in Miz-1 inactivation.
  • Assessed c-Myc's impact on cell cycle, transformation, and apoptosis in primary human fibroblasts.

Main Results:

  • Miz-1 inactivation was dispensable for c-Myc-driven cell cycle progression and transformation in vitro.
  • c-Myc-induced apoptosis in fibroblasts upon growth factor withdrawal critically depends on Miz-1 inactivation.
  • This study provides the first experimental evidence for Miz-1 inactivation's requirement in a c-Myc biological function.

Conclusions:

  • Miz-1 inactivation is essential for c-Myc-mediated apoptosis but not for cell cycle progression or transformation.
  • These findings clarify how c-Myc orchestrates opposing cellular outcomes.
  • The study highlights Miz-1 as a crucial target for understanding c-Myc's complex roles in cancer.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...